Brolucizumab
Beovu (brolucizumab) is a brand-name ophthalmic injection medication used to treat certain eye conditions that affect vision. It is prescribed for adults with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME), both of which involve abnormal blood vessel growth in the retina that can lead to vision loss if left untreated.
Beovu is an anti-VEGF eye injection used to treat wet AMD and diabetic macular edema by reducing abnormal blood vessel growth in the retina.
Key facts at a glance
- RxNorm
- 2204921
- Generic
- Beovu
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Beovu is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). These conditions involve the growth of abnormal blood vessels beneath the retina that can leak fluid and blood, leading to vision damage and loss.
Beovu is a humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, it reduces angiogenesis (new blood vessel formation) and vascular permeability, thereby decreasing fluid leakage and swelling in the retina.
Beovu is administered as an intravitreal injection (into the eye) by a qualified healthcare professional, typically every 4 weeks initially, then less frequently. Common side effects may include eye pain, cataract, conjunctival hemorrhage, and increased intraocular pressure. Rare but serious risks include endophthalmitis and retinal detachment. Patients should report any eye pain, vision changes, or signs of infection immediately.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 3, 2026. · Read our editorial policy